Tags

Type your tag names separated by a space and hit enter

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Cytokine Growth Factor Rev. 2020 08; 54:51-62.CG

Abstract

Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.

Authors+Show Affiliations

Department of Medical Biology, Medical Faculty, Ege University, Izmir, Turkey. Electronic address: bakiye.goker.bagca@ege.edu.tr.Department of Medical Biology, Medical Faculty, Ege University, Izmir, Turkey.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32636055

Citation

Goker Bagca, Bakiye, and Cigir Biray Avci. "The Potential of JAK/STAT Pathway Inhibition By Ruxolitinib in the Treatment of COVID-19." Cytokine & Growth Factor Reviews, vol. 54, 2020, pp. 51-62.
Goker Bagca B, Biray Avci C. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine Growth Factor Rev. 2020;54:51-62.
Goker Bagca, B., & Biray Avci, C. (2020). The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine & Growth Factor Reviews, 54, 51-62. https://doi.org/10.1016/j.cytogfr.2020.06.013
Goker Bagca B, Biray Avci C. The Potential of JAK/STAT Pathway Inhibition By Ruxolitinib in the Treatment of COVID-19. Cytokine Growth Factor Rev. 2020;54:51-62. PubMed PMID: 32636055.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. AU - Goker Bagca,Bakiye, AU - Biray Avci,Cigir, Y1 - 2020/06/20/ PY - 2020/06/16/received PY - 2020/06/17/revised PY - 2020/06/18/accepted PY - 2020/7/9/pubmed PY - 2020/9/29/medline PY - 2020/7/9/entrez KW - COVID-19 KW - Cytokine storm KW - JAK/STAT pathway KW - Ruxolitinib KW - SARS-CoV-2 SP - 51 EP - 62 JF - Cytokine & growth factor reviews JO - Cytokine Growth Factor Rev VL - 54 N2 - Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway. SN - 1879-0305 UR - https://www.unboundmedicine.com/medline/citation/32636055/The_potential_of_JAK/STAT_pathway_inhibition_by_ruxolitinib_in_the_treatment_of_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1359-6101(20)30158-1 DB - PRIME DP - Unbound Medicine ER -